Real-time
Euronext Bruxelles
12:38:19 2024-03-28 pm EDT
5-day change
1st Jan Change
366.1
EUR
-0.57%
-1.56%
+6.58%
Argenx : BlackRock Inc. - argenx SE - Breda
January 11, 2023 at 03:28 pm EST
BlackRock Inc. - argenx SE - Breda
BlackRock Inc. - argenx SE - Breda
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction 10 jan 2023
Person obliged to notify BlackRock Inc.
Issuing institution argenx SE
Registration Chamber of Commerce 24435214
Place of residence Breda
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Type of share Contract for difference
Number of shares 3.045,00
Number of voting rights 4.195,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement In contanten
Type of share Gewoon aandeel
Number of shares 1.923.400,00
Number of voting rights 2.368.530,00
Capital interest Reëel
Voting rights Reëel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement
Type of share Gewoon aandeel
Number of shares 112.227,00
Number of voting rights 117.568,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement Fysieke levering
Type of share Certificaat van aandeel
Number of shares 721.074,00
Number of voting rights 787.277,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(Blackrock, Inc.)
Settlement
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Type Kapitaalbelang
Total holding 4,98 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 3,47 %
Indirectly potential 1,51 %
Type Stemrecht
Total holding 5,92 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 4,28 %
Indirectly potential 1,64 %
Date last update: 11 January 2023
Disclaimer
arGEN-X SE published this content on 10 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 11 January 2023 20:27:08 UTC .
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
Mar. 27
CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating
Mar. 26
MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia
Mar. 26
MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia
Mar. 26
CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Mar. 21
MT
US Futures, European Stocks Rise After Fed Maintains Outlook
Mar. 21
DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
Mar. 13
MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating
Mar. 05
MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating
Mar. 01
MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating
Mar. 01
MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...
Feb. 29
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
Feb. 29
MT
Sector Update: Health Care Stocks Advance Premarket Thursday
Feb. 29
MT
Sector Update: Health Care
Feb. 29
MT
Transcript : Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell
Feb. 29
MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 29
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
Feb. 20
MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo
Feb. 20
MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo
Feb. 20
MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Feb. 20
CI
Wolfe Research Starts Argenx With Peer Perform Rating
Feb. 15
MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Feb. 12
MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading
Feb. 09
MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
Feb. 06
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
More about the company
Last Close Price
366.1
EUR
Average target price
439.3
EUR
Spread / Average Target
+19.99%
Consensus
1st Jan change
Capi.
+6.58% 23.48B +2.73% 108B +9.59% 103B -12.59% 21.93B -3.29% 19.68B -36.53% 18.37B -13.29% 16.33B +4.68% 13.72B +34.25% 12.15B -6.78% 10.2B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1